OnKure reports Q2 results, PIKture-01 trial on track for Q4 data, cash runway into Q4 2026.

• OnKure Therapeutics reports Q2 2025 financial results • PIKture-01 trial on track for Q4 2025 data on OKI-219 in solid tumors • New expansion arms for PIKture-01 initiated in breast cancer • $83.4M cash position expected to last until Q4 2026

Title: OnKure Therapeutics Reports Q2 2025 Financial Results

OnKure Therapeutics, Inc. (OTC: ONKT) has released its quarterly earnings report for the period ending June 30, 2025. The company reported a cash position of $83.4 million and an accumulated deficit of $186.0 million, with management stating that the liquidity is sufficient to fund the current operating plan for at least the next 12 months [1].

The quarterly results reflect ongoing investment in drug development, with research and development (R&D) expenses totaling $12.6 million for the quarter and $25.6 million for the six months ended June 30, 2025. This resulted in a six-month net loss of $31.3 million. The increase in R&D spending was driven by higher clinical trial and manufacturing costs [1].

OnKure Therapeutics completed a $65.0 million concurrent financing at the closing of the merger with Reneo and is advancing its lead candidate, OKI-219, in a Phase 1a/1b trial. The company has also initiated new expansion arms for its PIKture-01 trial in breast cancer, with the primary trial on track for Q4 2025 data release [1].

The filing also discloses two lawsuits alleging disclosure issues related to the merger, which remain unresolved. OnKure Therapeutics states it will continue to evaluate macroeconomic and legislative tax changes [1].

References
[1] https://www.stocktitan.net/sec-filings/RPHM/10-q-reneo-pharmaceuticals-inc-common-stock-quarterly-earnings-report-e6b789e33be5.html